Roles of microRNA-221/222 in type 2 diabetic patients with post-menopausal breast cancer

Li, M. Y.; Pan, Shuangshuang; Qiu, Anni

doi:10.4238/gmr.15027259

Cited by 21 publications

(15 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The main characteristics extracted from various datasets are summarized in Table 1, which includes the number of patients investigated, the measurement platform, type of sample used and the identity of miRNAs in the study [23,24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53,54,55,56,57,58,59,60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78,79,80,81]. Comparing results from multiple tissues provides an overall view of the impact of miRNAs in T2DM pathology.…”

Section: Resultsmentioning

confidence: 99%

A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus

Ding

Liang

et al. 2017

IJMS

109

View full text Add to dashboard Cite

MicroRNAs (miRNAs) are small noncoding RNAs that modulate the cellular transcriptome at the post-transcriptional level. miRNA plays important roles in different disease manifestation, including type 2 diabetes mellitus (T2DM). Many studies have characterized the changes of miRNAs in T2DM, a complex systematic disease; however, few studies have integrated these findings and explored the functional effects of the dysregulated miRNAs identified. To investigate the involvement of miRNAs in T2DM, we obtained and analyzed all relevant studies published prior to 18 October 2016 from various literature databases. From 59 independent studies that met the inclusion criteria, we identified 158 dysregulated miRNAs in seven different major sample types. To understand the functional impact of these deregulated miRNAs, we performed targets prediction and pathway enrichment analysis. Results from our analysis suggested that the altered miRNAs are involved in the core processes associated with T2DM, such as carbohydrate and lipid metabolisms, insulin signaling pathway and the adipocytokine signaling pathway. This systematic survey of dysregulated miRNAs provides molecular insights on the effect of deregulated miRNAs in different tissues during the development of diabetes. Some of these miRNAs and their mRNA targets may have diagnostic and/or therapeutic utilities in T2DM.

show abstract

Section: Resultsmentioning

confidence: 99%

A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus

Ding

Liang

et al. 2017

IJMS

109

View full text Add to dashboard Cite

show abstract

“…14 The pleiotropic role of miR not only gives a selective pressure against their mutations, but it explains the involvement of miRs in several biologic processes. 15 This property is well described for several miRs and might explain the link between diseases co-occurrence. The epigenetic origin of the relationship between obesity and breast cancer (BC) will be investigated in the present paper.…”

Section: Introductionmentioning

confidence: 77%

Expression and polymorphism of micro-RNA according to body mass index and breast cancer presentation in Tunisian patients

Belaiba

Medimegh

Ammar

et al. 2018

Journal of Leukocyte Biology

View full text Add to dashboard Cite

Micro-RNAs (miRs) constitute a class of small noncoding RNAs implicated in the regulation of gene expression by binding to target mRNAs. A miR can target several mRNAs, being involved in different biologic processes and pathologies. This pleiotropic function might explain the link between diseases co-occurrence. Epigenetic origin of the link between obesity and breast cancer (BC) is investigated in a cohort of Tunisian patients, focusing on polymorphism at germline level (miR-146a) and on expression in mammary tumors (miR-21, miR-146a, and miR-34a), according to body mass index (BMI) and clinico-pathologic features. The measure of miR expression in 60 mammary tumors was realized using quantitative RT-PCR. Study of rs 2910164 in miR-146a was performed by PCR and direct sequencing using blood DNA of 83 affected women and 50 unrelated subjects from Great Tunis. MiR-21, miR-146a, and miR-34a have been quantified in breast tumor according to BMI. MiR-21 is significantly more expressed in tumors of obese women comparatively to nonobese patients. On the contrary, miR-34a is decreased in tumors of obese women. Moreover, in obese BC patients, a significant increase in both miR-21 and miR-146a expression is revealed in cases with lymph node metastasis. The polymorphism at rs 2910164 (miR-146a) locus was not shown as a risk factor for BC. However the mutant CC genotype was revealed to be associated with a risk for bad outcome of the disease. Chronic inflammation in obese women would be linked to aggressive breast tumors via induction of oncomiRs overexpression and decrease of tumor suppressor miRs. K E Y W O R D Sbody mass index, mammary tumors, miR-146a, miR-21, miR-34a tions, transcription of these miRs is at baseline levels. In the context of inflammation, several stimuli such as cytokines (TNF-, IL-1 ) or ligands of TLR such LPS are capable of regulating the expression of these

show abstract

“…Furthermore, Li et al showed an upregulation in miR-222 serum levels of T2D Chinese women. 38 On the contrary, investigation of miRs expression pattern in the Italian population performed by De Candia et al revealed a decline in miR-222 expression of T2D subjects, which was inversely correlated with glycated hemoglobin and modulated in the plasma samples of diabetic subjects. 39 Inconsistent results concerning miR-15a and miR-222 expressions mentioned in previously performed studies can be attributed to different factors.…”

Section: Discussionmentioning

confidence: 95%

<p>Circulating miR-15a and miR-222 as Potential Biomarkers of Type 2 Diabetes</p>

Sadeghzadeh

Ashkezari

Seifati

et al. 2020

DMSO

View full text Add to dashboard Cite

Background: In recent years, considerable attention has been paid to the role of microRNAs (miRs) as biomarkers in type 2 diabetes (T2D). The aim of the study was to evaluate the expression levels of miR-15a and miR-222 in diabetic, pre-diabetic, and healthy individuals. Materials and Methods: Ninety individuals, who were referred to the Yazd diabetic center, were enrolled in this study and then classified into three groups as healthy, pre-T2D, and diabetic based on the clinical manifestations. Real-time PCR was performed to explore miRs expression in the plasma samples of the studied population. The correlation between the biochemical characteristic and the expression of these miRs as well as specificity and sensitivity of different clinical markers in healthy and pre-diabetic groups was evaluated. Results: miR-222 expression was significantly upregulated in the pre-T2D cases compared to the control subjects (P<0.001), while no significant difference was found between the pre-T2D and T2D groups (P<0.05). The expression of miR-15a was statistically downregulated in the pre-T2D and T2D subjects (P<0.05). The receiver operating characteristic (ROC) curve analysis of miR-15a expression with a cutoff point of 1.12 resulted in the area under the curve (AUC) of 85% (95% CI 0.865-0.912; P<0.001) with 84% and 85% sensitivity and specificity, respectively. Similarly, for miR-222, the cutoff point of 4.03 and AUC of 86% (95% CI 0.875-0.943; P<0.001) discriminated against the pre-T2D and control subjects via the sensitivity and specificity of 86% and 87%, respectively. Moreover, miR-15a values showed a negative correlation with FG (R=−0.32, P=0.005); however, miR-222 values were positively correlated with FG (R=0.25, P=0.03) in the pre-T2D group. Furthermore, miR-222 values were correlated with OGTT in the pre-T2D group (R=0.27, P=0.001). In addition, LDL-C had a negative correlation with miR-222 values in the pre-T2D group (R=−0.23, P=0.02). Conclusion: This study indicated that the plasma expression levels of miR-222 and miR-15a can be considered as non-invasive, fast tools to separate the pre-T2D individuals from their healthy counterparts. Accordingly, this information could be used to predict the development of the disease as well as a direction for optimal therapy, thus refining outcomes in patients with diabetes.

show abstract

Roles of microRNA-221/222 in type 2 diabetic patients with post-menopausal breast cancer

Cited by 21 publications

References 27 publications

A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus

A Systematic Study of Dysregulated MicroRNA in Type 2 Diabetes Mellitus

Expression and polymorphism of micro-RNA according to body mass index and breast cancer presentation in Tunisian patients

<p>Circulating miR-15a and miR-222 as Potential Biomarkers of Type 2 Diabetes</p>

Contact Info

Product

Resources

About